Korean J Gastroenterol.  2013 Jul;62(1):78-81. 10.4166/kjg.2013.62.1.78.

New Paradigm for Treatment of Chronic Hepatitis C Virus Infection

• Chung WJ

• KMID: 1711285
• DOI: http://doi.org/10.4166/kjg.2013.62.1.78

Abstract

No abstract available.

MeSH Terms

Female
Gastroparesis/*diagnosis
Hernia, Diaphragmatic/*diagnosis
Humans
Stomach Volvulus/*diagnosis

Reference

References

1. Global surveillance and control of hepatitis C. Report of a WHO Consultation organized in collaboration with the Viral Hepatitis Prevention Board, Antwerp, Belgium. J Viral Hepat. 1999; 6:35–47.

2. Smith BD, Morgan RL, Beckett GA, et al. Centers for Disease Control and Prevention. Recommendations for the identification of chronic hepatitis C virus infection among persons born during 1945–1965. MMWR Recomm Rep. 2012; 61:1–32.

3. Singal AG, Volk ML, Jensen D, Di Bisceglie AM, Schoenfeld PS. A sustained viral response is associated with reduced liver-related morbidity and mortality in patients with hepatitis C virus. Clin Gastroenterol Hepatol. 2010; 8:280–288.

4. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998; 339:1485–1492.

5. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon al-fa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358:958–965.

6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002; 347:975–982.

7. McHutchison JG, Lawitz EJ, Shiffman ML, et al. IDEAL Study Team. Peginterferon alfa-2b or alfa-2a with ribavirin for treatment of hepatitis C infection. N Engl J Med. 2009; 361:580–593.

8. Welsch C, Jesudian A, Zeuzem S, Jacobson I. New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives. Gut. 2012; 61(Suppl 1):i36–i46.

9. McHutchison JG, Everson GT, Gordon SC, et al. Telaprevir with peginterferon and ribavirin for chronic HCV genotype 1 infection. N Engl J Med. 2009; 360:1827–1838.

10. Hézode C, Forestier N, Dusheiko G, et al. PROVE2 Study Team. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med. 2009; 360:1839–1850.

11. McHutchison JG, Manns MP, Muir AJ, et al. PROVE3 Study Team. Telaprevir for previously treated chronic HCV infection. N Engl J Med. 2010; 362:1292–1303.

12. Bartenschlager R, Ahlborn-Laake L, Mous J, Jacobsen H. Nonstructural protein 3 of the hepatitis C virus encodes a ser-ine-type proteinase required for cleavage at the NS3/4 and NS4/5 junctions. J Virol. 1993; 67:3835–3844.

13. Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM. Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol. 1993; 67:1385–1395.

14. Hijikata M, Mizushima H, Tanji Y, et al. Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. Proc Natl Acad Sci U S A. 1993; 90:10773–10777.

15. Rice CM. New insights into HCV replication: potential antiviral targets. Top Antivir Med. 2011; 19:117–120.

16. Einav S, Gerber D, Bryson PD, et al. Discovery of a hepatitis C target and its pharmacological inhibitors by microfluidic affinity analysis. Nat Biotechnol. 2008; 26:1019–1027.

17. Tellinghuisen TL, Marcotrigiano J, Rice CM. Structure of the zinc-binding domain of an essential component of the hepatitis C virus replicase. Nature. 2005; 435:374–379.

18. Foster TL, Gallay P, Stonehouse NJ, Harris M. Cyclophilin A interacts with domain II of hepatitis C virus NS5A and stimulates RNA binding in an isomerase-dependent manner. J Virol. 2011; 85:7460–7464.

19. Kim S, Welsch C, Yi M, Lemon SM. Regulation of the production of infectious genotype 1a hepatitis C virus by NS5A domain III. J Virol. 2011; 85:6645–6656.

20. Kowdley KV, Lawitz E, Crespo I, et al. Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatmentnaive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial. Lancet. 2013; 381:2100–2107.

21. Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368:1878–1887.

22. Gane EJ, Stedman CA, Hyland RH, et al. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013; 368:34–44.

23. Coelmont L, Hanoulle X, Chatterji U, et al. DEB025 (Alisporivir) inhibits hepatitis C virus replication by preventing a cyclophilin A induced cis-trans isomerisation in domain II of NS5A. PLoS One. 2010; 5:e13687.

24. Lanford RE, Hildebrandt-Eriksen ES, Petri A, et al. Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection. Science. 2010; 327:198–201.